Reckitt Benckiser Group (LON:RB) was upgraded by research analysts at UBS Group to a “buy” rating in a research note issued on Monday, Borsen Zeitung reports. The firm currently has a GBX 8,400 ($103.37) price objective on the stock, up from their prior price objective of GBX 5,700 ($70.15). UBS Group’s price target points to a potential upside of 13.02% from the company’s previous close.
Several other research firms have also weighed in on RB. Goldman Sachs Group raised their price objective on Reckitt Benckiser Group from GBX 6,300 ($77.53) to GBX 6,510 ($80.11) and gave the stock a “neutral” rating in a research note on Tuesday, June 16th. DZ Bank raised their price objective on Reckitt Benckiser Group from GBX 7,100 ($87.37) to GBX 7,800 ($95.99) and gave the stock a “buy” rating in a research note on Thursday, May 28th. Morgan Stanley reissued an “overweight” rating and set a GBX 7,000 ($86.14) price objective on shares of Reckitt Benckiser Group in a research note on Monday, May 18th. Royal Bank of Canada set a GBX 4,900 ($60.30) target price on Reckitt Benckiser Group and gave the stock a “sell” rating in a research report on Friday, June 5th. Finally, Societe Generale decreased their target price on Reckitt Benckiser Group from GBX 5,400 ($66.45) to GBX 5,200 ($63.99) and set a “sell” rating for the company in a research report on Thursday, June 4th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and thirteen have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of GBX 7,117.37 ($87.59).
Shares of LON RB opened at GBX 7,432 ($91.46) on Monday. The stock has a fifty day moving average price of GBX 7,055.16 and a two-hundred day moving average price of GBX 6,393.24. The company has a debt-to-equity ratio of 130.80, a quick ratio of 0.40 and a current ratio of 0.56. The firm has a market cap of $52.69 billion and a P/E ratio of -14.28. Reckitt Benckiser Group has a 1 year low of GBX 5,130 ($63.13) and a 1 year high of GBX 8,191.30 ($100.80).
In related news, insider Nicandro Durante bought 165 shares of the business’s stock in a transaction on Wednesday, May 27th. The shares were bought at an average cost of GBX 6,884 ($84.72) per share, for a total transaction of £11,358.60 ($13,978.10).
About Reckitt Benckiser Group
Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers acne treatment creams, facial washes, and cleansing pads; disinfection, hygiene, and first aid products; condoms, sex toys, and lubricants; heartburn and indigestion solutions; and cough and chest congestion, multi-symptom, and sinus remedies for adults and children under the Clearasil, Dettol, Durex, Gaviscon, and Mucinex brands.
Further Reading: What is the Book Value of a Share?
Receive News & Ratings for Reckitt Benckiser Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reckitt Benckiser Group and related companies with MarketBeat.com's FREE daily email newsletter.